Evidence map›Paper›PMID 21569354›Full record

ArticleBMC medical genomics2011

Detecting differential allelic expression using high-resolution melting curve analysis: application to the breast cancer susceptibility gene CHEK2.

Tú Nguyen-Dumont, Lars P Jordheim, Jocelyne Michelon, Nathalie Forey, Sandrine McKay-Chopin, Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer, Olga Sinilnikova, Florence Le Calvez-Kelm, Melissa C Southey, Sean V Tavtigian and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC medical genomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Tú Nguyen-DumontGenetic Cancer Susceptibility Group, IARC, 69372 Lyon, France.
Lars P Jordheim
Jocelyne Michelon
Nathalie Forey
Sandrine McKay-Chopin
Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer
Olga Sinilnikova
Florence Le Calvez-Kelm
Melissa C Southey
Sean V Tavtigian
Fabienne Lesueur
Centre International de Recherche sur le Cancer · FRCentre Léon Bérard · FRHuntsman Cancer Institute · USUniversité Claude Bernard Lyon 1 · FRUniversity of Melbourne · AU

Funding

COMMON AND RARE SEQUENCE VARIANTS IN BREAST CANCER RISKR01CA121245 · NCI · UNIVERSITY OF UTAH · PI TAVTIGIAN, SEAN VAHRAM · 2007 to 2021
$4.9M
CIHR CRN-87521-IC089832NCI NIH HHS R01 CA121245
6 · The paper itself

Abstract

backgroundThe gene CHEK2 encodes a checkpoint kinase playing a key role in the DNA damage pathway. Though CHEK2 has been identified as an intermediate breast cancer susceptibility gene, only a small proportion of high-risk families have been explained by genetic variants located in its coding region. Alteration in gene expression regulation provides a potential mechanism for generating disease susceptibility. The detection of differential allelic expression (DAE) represents a sensitive assay to direct the search for a functional sequence variant within the transcriptional regulatory elements of a candidate gene. We aimed to assess whether CHEK2 was subject to DAE in lymphoblastoid cell lines (LCLs) from high-risk breast cancer patients for whom no mutation in BRCA1 or BRCA2 had been identified.

methodsWe implemented an assay based on high-resolution melting (HRM) curve analysis and developed an analysis tool for DAE assessment.

resultsWe observed allelic expression imbalance in 4 of the 41 LCLs examined. All four were carriers of the truncating mutation 1100delC. We confirmed previous findings that this mutation induces non-sense mediated mRNA decay. In our series, we ruled out the possibility of a functional sequence variant located in the promoter region or in a regulatory element of CHEK2 that would lead to DAE in the transcriptional regulatory milieu of freely proliferating LCLs.

conclusionsOur results support that HRM is a sensitive and accurate method for DAE assessment. This approach would be of great interest for high-throughput mutation screening projects aiming to identify genes carrying functional regulatory polymorphisms.

Indexed as

AllelesGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseAllelic ImbalanceBreast NeoplasmsCell Line, TumorCheckpoint Kinase 2Codon, NonsenseDNA Mutational AnalysisExonsFemaleGenes, NeoplasmGenotypeHeterozygoteHumansNucleic Acid DenaturationCheckpoint Kinase 2CHEK2 protein, humanCodon, NonsenseProtein Serine-Threonine Kinases

Identifiers

PMID21569354
PMCPMC3112061
OpenAlexW2006760710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.